Pharmaceutical Preparations
Standard Industrial Classification: SIC 2834
Industry Insider Sentiment Analysis
The Pharmaceutical Preparations sector (SIC 2834) acts as a critical barometer for broader economic health. Our real-time monitoring reveals total transactions. Monitoring "cluster buying" is one of the most reliable leading indicators for future sector performance. By analyzing aggregate data across this specific Standard Industrial Classification, investors can filter out individual company volatility and identify high-conviction trends. When multiple directors and officers within the same industry move capital simultaneously, it often signals an upcoming sector-wide revaluation or a fundamental shift in supply chain dynamics that has yet to be recognized by the broader public market.
| Filing Date | Trade Date | Ticker | Company | Reporting Person | Relationship | Type | Price | Qty | Total, $ | Owned After |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025-05-06 03:28 | 2025-05-02 | CORT | CORCEPT THERAPEUTICS INC | BELANOFF JOSEPH K | Director, Officer | SELL | $72.90 | 40,000 | $2,915,920 | 2,941,985 |
| 2025-05-06 03:26 | 2025-05-01 | CORT | CORCEPT THERAPEUTICS INC | Lyon Joseph Douglas | Officer | OPT+S | $71.96 | 9,350 | $672,781 | 9,009 |
| 2025-05-06 01:21 | 2025-05-05 | CYTK | CYTOKINETICS INC | Callos Andrew | Officer | SELL | $36.68 | 4,002 | $146,793 | 60,687 |
| 2025-05-02 23:17 | 2025-05-01 | CNTA | Centessa Pharmaceuticals plc | HUSSAIN IQBAL J | Officer | OPT+S | $14.00 | 311 | $4,354 | 105,386 |
| 2025-05-03 03:00 | 2025-05-01 | JANX | Janux Therapeutics, Inc. | Meyer Andrew Hollman | Officer | OPT+S | $32.03 | 3,333 | $106,745 | 82,139 |
| 2025-05-03 02:55 | 2025-05-01 | RNA | Avidity Biosciences, Inc. | Gallagher Kathleen P. | Officer | OPT+S | $32.40 | 5,875 | $190,324 | 50,554 |
| 2025-05-03 01:18 | 2025-05-02 | NRIX | Nurix Therapeutics, Inc. | van Houte Hans | Officer | SELL | $11.33 | 6,198 | $70,243 | 33,724 |
| 2025-05-03 00:04 | 2025-04-30 | ABT | Abbott Laboratories | Blount Sally E. | Director | SELL | $129.66 | 2,600 | $337,116 | 34,058 |
| 2025-05-02 23:38 | 2025-05-01 | IONS | IONIS PHARMACEUTICALS INC | Hayden Michael R | Director | BUY | $31.86 | 15,000 | $477,900 | 50,219 |
| 2025-05-03 03:27 | 2025-05-01 | AMPH | Amphastar Pharmaceuticals Inc. | Petersen Floyd F. | Director | SELL | $24.08 | 500 | $12,041 | 73,409 |
| 2025-05-02 23:43 | 2025-05-01 | INSM | INSMED Inc | Lewis William | Director, Officer | OPT+S | $72.57 | 6,830 | $495,667 | 233,924 |
| 2025-05-02 23:31 | 2025-05-01 | UTHR | UNITED THERAPEUTICS Corp | MAHON PAUL A | Officer | OPT+S | $300.93 | 11,000 | $3,310,201 | 36,781 |
| 2025-05-03 03:00 | 2025-05-02 | ACAD | Acadia Pharmaceuticals Inc. | Kihara James | Officer | OPT+S | $14.60 | 1,327 | $19,374 | 23,526 |
| 2025-05-03 02:59 | 2025-05-02 | ACAD | Acadia Pharmaceuticals Inc. | Schneyer Mark C. | Officer | OPT+S | $14.60 | 3,498 | $51,071 | 62,773 |
| 2025-05-02 17:29 | 2024-12-18 | PRTA | PROTHENA CORP PUBLIC LTD CO | SCULLY WILLIAM P | 10% owner | BUY | $13.26 | 207,436 | $2,749,917 | 735,993 |
| 2025-05-01 23:45 | 2025-04-29 | NUVL | Nuvalent, Inc. | Noci Darlene | Officer | OPT+S | $74.56 | 4,000 | $298,240 | 48,034 |
| 2025-05-02 01:26 | 2025-04-29 | KNSA | Kiniksa Pharmaceuticals International, plc | Moat Ross | Officer | OPT+S | $25.96 | 87,269 | $2,265,337 | 9,415 |
| 2025-05-02 01:24 | 2025-04-29 | KNSA | Kiniksa Pharmaceuticals International, plc | Ragosa Mark | Officer | OPT+S | $26.56 | 88,395 | $2,347,338 | 27,009 |
| 2025-05-01 23:53 | 2025-04-29 | RYTM | RHYTHM PHARMACEUTICALS, INC. | Cramer Pamela J. | Officer | OPT+S | $65.09 | 7,031 | $457,663 | 19,209 |
| 2025-05-01 23:52 | 2025-04-29 | RYTM | RHYTHM PHARMACEUTICALS, INC. | Mazabraud Yann | Officer | SELL | $65.08 | 6,745 | $438,946 | 37,655 |
| 2025-05-02 02:07 | 2025-04-30 | ACRV | Acrivon Therapeutics Inc. | PERCEPTIVE ADVISORS LLC | 10% owner | SELL | $1.38 | 736,767 | $1,017,917 | 3,104,139 |
| 2025-04-30 23:15 | 2025-04-28 | LQDA | Liquidia Corp | Adair Jason | Officer | SELL | $14.24 | 455 | $6,479 | 183,849 |
| 2025-05-01 01:59 | 2025-04-28 | ELVN | Enliven Therapeutics, Inc. | Hohl Benjamin | Officer | OPT+S | $18.69 | 3,250 | $60,738 | 23,000 |
| 2025-05-01 02:35 | 2025-04-30 | NRIX | Nurix Therapeutics, Inc. | Hansen Gwenn | Officer | OPT+S | $11.50 | 3,377 | $38,841 | 61,516 |
| 2025-05-01 02:35 | 2025-04-30 | NRIX | Nurix Therapeutics, Inc. | Ring Christine | Officer | OPT+S | $11.50 | 2,894 | $33,286 | 37,318 |
| 2025-05-01 02:35 | 2025-04-30 | NRIX | Nurix Therapeutics, Inc. | van Houte Hans | Officer | OPT+S | $11.50 | 2,438 | $28,041 | 39,922 |
| 2025-04-30 23:17 | 2025-03-27 | HOWL | Werewolf Therapeutics, Inc. | MPM BioVentures 2014, L.P. | 10% owner | SELL | $1.05 | 1,963 | $2,061 | 3,208,793 |
| 2025-05-01 00:07 | 2025-04-30 | ZNTL | Zentalis Pharmaceuticals, Inc. | Myers Scott Dunseth | Director | BUY | $1.40 | 21,000 | $29,373 | 281,192 |
| 2025-04-30 23:09 | 2025-03-27 | HOWL | Werewolf Therapeutics, Inc. | EVNIN LUKE | Director, 10% owner | SELL | $1.05 | 2,425 | $2,546 | 4,309,860 |
| 2025-04-30 23:08 | 2025-03-27 | HOWL | Werewolf Therapeutics, Inc. | GADICKE ANSBERT | 10% owner | SELL | $1.05 | 4,386 | $4,605 | 6,718,670 |
| 2025-04-29 23:04 | 2025-04-25 | MRK | Merck & Co., Inc. | Smart Dalton E. III | Officer | OPT+S | $82.76 | 4,262 | $352,723 | 7,778 |
| 2025-04-29 23:58 | 2025-04-25 | CNTA | Centessa Pharmaceuticals plc | HUSSAIN IQBAL J | Officer | OPT+S | $14.00 | 5,689 | $79,658 | 105,386 |
| 2025-04-29 13:14 | 2025-04-25 | GLSI | Greenwich LifeSciences, Inc. | Patel Snehal | Director, Officer, 10% owner | BUY | $9.88 | 3,600 | $35,568 | 5,570,602 |
| 2025-04-30 01:14 | 2025-04-25 | BMY | BRISTOL MYERS SQUIBB CO | Hirawat Samit | Officer | BUY | $47.58 | 4,250 | $202,215 | 83,513 |
| 2025-04-30 02:26 | 2025-04-25 | ACRV | Acrivon Therapeutics Inc. | PERCEPTIVE ADVISORS LLC | 10% owner | SELL | $1.81 | 1,519,952 | $2,744,881 | 3,840,906 |
| 2025-04-29 23:33 | 2025-04-29 | CYTK | CYTOKINETICS INC | Blum Robert I | Director, Officer | SELL | $40.96 | 5,000 | $204,800 | 417,629 |
| 2025-04-28 14:07 | 2025-02-07 | ZBIO | Zenas BioPharma, Inc. | Xiao Ting | Director | BUY | $7.76 | 10,000 | $77,600 | 10,000 |
| 2025-04-29 01:22 | 2025-04-24 | AKRO | Akero Therapeutics, Inc. | Rolph Timothy | Officer | OPT+S | $41.03 | 6,250 | $256,438 | 169,721 |
| 2025-04-26 02:01 | 2025-03-13 | MLYS | Mineralys Therapeutics, Inc. | Slingsby Brian Taylor | Director, 10% owner | BUY | $13.50 | 259,259 | $3,499,997 | 8,903,838 |
| 2025-04-26 03:20 | 2025-04-25 | CNTA | Centessa Pharmaceuticals plc | Weinhoff Gregory M | Officer | SELL | $13.61 | 11,742 | $159,857 | 122,279 |
| 2025-04-24 23:28 | 2025-04-22 | BBIO | BridgeBio Pharma, Inc. | Kumar Neil | Director, Officer | SELL | $34.11 | 75,000 | $2,558,025 | 4,873,447 |
| 2025-04-24 23:40 | 2025-04-23 | KPTI | Karyopharm Therapeutics Inc. | Rangwala Reshma | Officer | SELL | $6.17 | 419 | $2,585 | 28,853 |
| 2025-04-24 23:06 | 2025-04-22 | RCKT | ROCKET PHARMACEUTICALS, INC. | Militello John | Officer | SELL | $7.16 | 718 | $5,139 | 65,039 |
| 2025-04-25 00:20 | 2025-04-22 | PTCT | PTC THERAPEUTICS, INC. | Klein Matthew B. | Director, Officer | SELL | $48.74 | 2,804 | $136,656 | 273,234 |
| 2025-04-23 23:15 | 2025-04-21 | LQDA | Liquidia Corp | Saggar Rajeev | Officer | SELL | $13.67 | 2,450 | $33,492 | 263,152 |
| 2025-04-24 03:00 | 2025-04-21 | JANX | Janux Therapeutics, Inc. | Meyer Andrew Hollman | Officer | OPT+S | $30.00 | 3,334 | $100,020 | 82,139 |
| 2025-04-23 23:44 | 2025-04-21 | KNSA | Kiniksa Pharmaceuticals International, plc | Moat Ross | Officer | SELL | $20.29 | 18,259 | $370,475 | 9,415 |
| 2025-04-24 00:09 | 2025-04-21 | ELVN | Enliven Therapeutics, Inc. | Lyssikatos Joseph P | Officer | SELL | $16.07 | 5,000 | $80,366 | 997,688 |
| 2025-04-24 01:00 | 2025-04-21 | TBPH | Theravance Biopharma, Inc. | Farnum Rhonda | Officer | SELL | $9.00 | 4,000 | $36,000 | 370,038 |
| 2025-04-23 23:30 | 2025-04-22 | PTGX | Protagonist Therapeutics, Inc | Ali Asif | Officer | SELL | $46.00 | 1,756 | $80,776 | 61,065 |
Sector-Wide Insider Alpha
Analyzing insider movements across the Pharmaceutical Preparations sector provides a macro-view of executive conviction. When multiple leaders in different companies within the same SIC code (2834) simultaneously buy shares, it often indicates an industry-wide undervaluation or a positive shift in market cycles.
SEC Filings in Pharmaceutical Preparations
Every transaction in the Pharmaceutical Preparations industry is reported via Form 4 disclosures. By filtering these filings by industry, investors can detect institutional-scale sentiment shifts before they are reflected in broader market indices, following the capital flow of those with intimate industry knowledge.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.